Invesco
AEGR

Invesco’s Aegerion Pharmaceuticals AEGR Stock Holding History

Invesco’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-287
Closed -$5K – 4202
2015
Q2 		$5K Buy
+287
New +$6.21K ﹤0.01% 4258
2013
Q4 		– Sell
-31,336
Closed -$2.69M – 4400
2013
Q3 		$2.69M Buy
31,336
+19,081
+156% +$1.62M ﹤0.01% 2340
2013
Q2 		$776K Buy
+12,255
New +$651K ﹤0.01% 3042

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco's AEGR Position: Q3 2015 in Review

Invesco sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2015, closing a stake of 287 shares — an estimated $5K sold.

Invesco first reported a position in AEGR in Q2 2013 and held it in 3 quarters. The position peaked at $2.69M in Q3 2013. 96 funds tracked by Wall St. Rank hold AEGR as of Q3 2015.

  • Invesco reported no remaining Aegerion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Invesco sold 287 Aegerion Pharmaceuticals shares in Q3 2015, an estimated $5K.
  • Invesco first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Invesco's Aegerion Pharmaceuticals position peaked at $2.69M in Q3 2013.
  • 96 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2015.

Based on Invesco's 13F filing for Q3 2015, filed 16 Nov 2015.